Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2017: Deal trends, players, financials and forecasts

Be the first to review this product

Availability: In stock

$2,995.00

Quick Overview

The Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the worlds leading healthcare companies.

Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2017: Deal trends, players, financials and forecasts
Publication date Sep 2017
Publisher Current Partnering
Number of pages 500+
Report edition 2
Product code CP21131
ISBN n/a
Product type Research report
Available formats PDF

* Required Fields

$2,995.00

The Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2017: Deal trends, players, financials and forecasts report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:

 

  • Monoclonal antibodies
    • Murine mAb
    • Chimeric mAb
    • Humanized mAb
    • Human aAb

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading monoclonal antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2010. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.

 

Key benefits

 

Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2017 provides the reader with the following key benefits:

 

  • In-depth understanding of monoclonal antibodies deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of monoclonal antibodies agreements with numerous real life case studies
  • Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world’s biopharma companies
  • Identify the leading monoclonal antibody partnering companies
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2017 is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

 

Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2017 includes:

 

o  Trends in monoclonal antibodies dealmaking in the biopharma industry since 2010

o  Analysis of monoclonal antibodies deal structure

o  Access to headline, upfront, milestone and royalty data

o  Access to over 700 monoclonal antibodies deal records

o  The leading monoclonal antibodies deals by value since 2010

o  Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2010

 

In Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2017, the available deals are listed by:

 

o  Company A-Z

o  Headline value

o  Stage of development at signing

o  Deal component type

o  Monoclonal antibodies type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2017 report provides comprehensive access to available deals and contract documents for over 700 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise monoclonal antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2017 provides the reader with the following key benefits:

 

  • In-depth understanding of monoclonal antibodies deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Acces to the structure of monoclonal antibodies agreements with numerous real life case studies
  • Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of monoclonal antibodies deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading monoclonal antibodies deals by value since 2010
  • Identify the most active monoclonal antibodies dealmakers since 2010
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in monoclonal antibody dealmaking


2.1. Introduction
2.2. Monoclonal antibody partnering over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody partnering by deal type
2.5. Monoclonal antibody partnering by therapy area
2.6. Deal terms for monoclonal antibody partnering
2.6.1 Monoclonal antibody partnering headline values
2.6.2 Monoclonal antibody deal upfront payments
2.6.3 Monoclonal antibody deal milestone payments
2.6.4 Monoclonal antibody royalty rates

 

Chapter 3 – Leading monoclonal antibody deals

 

3.1. Introduction
3.2. Top monoclonal antibody deals by value

 

Chapter 4 – Most active monoclonal antibody dealmakers

 

4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody partnering company profiles

 

Chapter 5 – Monoclonal antibody contracts dealmaking directory

 

5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory

 

Chapter 6 – Monoclonal antibody dealmaking by technology type

 

Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Monoclonal antibody deals by company A-Z

 

Appendix 2 – Monoclonal antibody deals by stage of development

 

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

 

Appendix 3 – Monoclonal antibody deals by deal type

 

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

 

Appendix 4 – Monoclonal antibody deals by therapy area

 

Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Hematology
Hospital care
Immunology
Infectives
Metabolic
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory

 

Appendix 5 –Deal type definitions


About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering


Table of figures

 

Figure 1: Therapeutic antibody definitions
Figure 2: Monoclonal antibody partnering since 2010
Figure 3: Active monoclonal antibody dealmaking activity since 2010
Figure 4: Monoclonal antibody partnering by deal type since 2010
Figure 5: Monoclonal antibody partnering by disease type since 2010
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2010
Figure 11: Most active monoclonal antibody dealmakers since 2010
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events

Pricing options

  • $2,995: single-user
  • $4,495: multi-user
  • $8,995: single site license
  • $14,995: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

You may also be interested in the following product(s)

Global Antibody Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

Global Antibody Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

$2,995.00
     

Product Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

© 2017 Wildwood Ventures Ltd.